Skip to Main Content

Paper Details

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.
Cell Res
77
2018
Author NameAffiliation
Alejandra BrunaDepartment of Oncology and Cancer Research UK Cambridge Institute, University of Cambridge
Sake van WageningenOncode Institute, The Netherlands Cancer Institute
Oscar M RuedaDepartment of Oncology and Cancer Research UK Cambridge Institute, University of Cambridge
Carlos CaldasDepartment of Oncology and Cancer Research UK Cambridge Institute, University of Cambridge
Carlos CaldasNIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust
Lodewyk F A WesselsOncode Institute, The Netherlands Cancer Institute
  • 1 - 6

Datasets